Literature DB >> 25641559

A key lysine residue in the AXH domain of ataxin-1 is essential for its ubiquitylation.

A-ram Kang1, Si Hoon Park1, Soyeon Lee1, Do-Young Choi2, Kwang Pyo Kim2, Hyun Kyu Song1, Sunghoi Hong3, Seongman Kang4.   

Abstract

Spinocerebellar ataxia type 1 (SCA1), an autosomal-dominant neurodegenerative disorder, is caused by expansion of the polyglutamine tract within ataxin-1 (ATXN1). The AXH domain of ATXN1 can mediate neurodegeneration through its interaction with other proteins. We have previously showed that the ubiquitin-conjugating enzyme UbcH6 modulates the transcriptional repression activity of ATXN1 through ubiquitylation. In the present study, we sought to identify sites in the AXH domain that are ubiquitylated by UbcH6. Systematic replacement of each lysine residue in the AXH domain revealed that the lysine at 589 (K589) of ATXN1 is essential for its ubiquitylation by UbcH6. Mass spectrometry studies further confirmed the ubiquitylation site. Interestingly, protein aggregation was significantly enhanced in mutant AXH K589R, implying that the aggregation is strongly associated with the level of ATXN1 expression. Our study may suggest a therapeutic potential of UbcH6 in the treatment of SCA1.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Ataxin-1; Protein aggregation; Protein degradation; Spinocerebellar ataxia type 1 (SCA1); UbcH6; Ubiquitylation

Mesh:

Substances:

Year:  2015        PMID: 25641559     DOI: 10.1016/j.bbapap.2015.01.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

Review 1.  Exploring the Role of Posttranslational Modifications in Spinal and Bulbar Muscular Atrophy.

Authors:  Neha Gogia; Luhan Ni; Victor Olmos; Fatema Haidery; Kimberly Luttik; Janghoo Lim
Journal:  Front Mol Neurosci       Date:  2022-06-03       Impact factor: 6.261

2.  PAK1 regulates ATXN1 levels providing an opportunity to modify its toxicity in spinocerebellar ataxia type 1.

Authors:  Vitaliy V Bondar; Carolyn J Adamski; Tarik S Onur; Qiumin Tan; Li Wang; Javier Diaz-Garcia; Jeehye Park; Harry T Orr; Juan Botas; Huda Y Zoghbi
Journal:  Hum Mol Genet       Date:  2018-08-15       Impact factor: 6.150

3.  Ataxin-1 regulates epithelial-mesenchymal transition of cervical cancer cells.

Authors:  A-Ram Kang; Hyoung-Tae An; Jesang Ko; Seongman Kang
Journal:  Oncotarget       Date:  2017-03-14

Review 4.  Chaperones in Polyglutamine Aggregation: Beyond the Q-Stretch.

Authors:  E F E Kuiper; Eduardo P de Mattos; Laura B Jardim; Harm H Kampinga; Steven Bergink
Journal:  Front Neurosci       Date:  2017-03-23       Impact factor: 4.677

Review 5.  Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies.

Authors:  Chunchen Xiang; Shun Zhang; Xiaoyu Dong; Shuang Ma; Shuyan Cong
Journal:  Front Mol Neurosci       Date:  2018-05-15       Impact factor: 5.639

Review 6.  Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective.

Authors:  François Le Guerroué; Richard J Youle
Journal:  Cell Death Differ       Date:  2020-11-18       Impact factor: 12.067

7.  Ataxin-1 is involved in tumorigenesis of cervical cancer cells via the EGFR-RAS-MAPK signaling pathway.

Authors:  A-Ram Kang; Hyoung-Tae An; Jesang Ko; Eui-Ju Choi; Seongman Kang
Journal:  Oncotarget       Date:  2017-10-10

Review 8.  Roles of Post-translational Modifications in Spinocerebellar Ataxias.

Authors:  Linlin Wan; Keqin Xu; Zhao Chen; Beisha Tang; Hong Jiang
Journal:  Front Cell Neurosci       Date:  2018-09-19       Impact factor: 5.505

9.  ATXN1 N-terminal region explains the binding differences of wild-type and expanded forms.

Authors:  Sara Rocha; Jorge Vieira; Noé Vázquez; Hugo López-Fernández; Florentino Fdez-Riverola; Miguel Reboiro-Jato; André D Sousa; Cristina P Vieira
Journal:  BMC Med Genomics       Date:  2019-10-26       Impact factor: 3.063

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.